Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Anokion (Group)

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company's antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion's approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications. *

 

Period Start 2014-05-05 splitoff before
  Predecessor EPFL (Ecole Polytechnique Fédérale de Lausanne)
Products Industry drug development
  Industry 2 immuno modulatory compound (IMO)
Persons Person Geraghty, Deborah (Anokion 202210 CEO)
  Person 2 Hubbell, Jeffrey A. (Anokion 201701 Chairman + CSO + Academic Founder + Prof at Univ Chicago + before at EPFL)
     
Region Region Ecublens VD
  Country Switzerland
  Street 1A Chemin de la Dent d’Oche
EPFL Innovation Park-L
  City 1024 Ecublens VD
  Tel +41-21-693-7237
    Address record changed: 2022-10-29
     
Basic data Employees n. a.
     
    * Document for »About Section«: 
     
   
Record changed: 2023-07-10

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Anokion (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px




» top